// App-Quantinova.ai

BSH2020‐PO‐152 : Comparison of lost productivity due to eculizumab and ravulizumab treatments for paroxysmal nocturnal hemoglobinuria in France, Germany, Italy, Russia, Spain, the UK, and the USA

Researchers

Presenter

  • A. R. Levy

Principal Investigators

  • Y. Patel

  • A. Briggs

  • J. Schneider

  • K.-J. Myren

  • I. Tomazos

Medical Centers

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

  • EScience, University of Glasgow, Glasgow, UK

  • Avalon Health Economics, Morristown, NJ

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved